#### 1 **Type of Article:** Original Article

#### 2 Title: Platelet hyperactivity in patients of vascular dementia

- 3 **Running Title:** Platelet hyperactivity in VaD patients
- 4 Name & Address of authors and their Institution:
- 5 1) Priya Dev, PhD Scholar, Department of Neurology, Institute of Medical Sciences,
- Banaras Hindu University, Varanasi-221005, Uttar Pradesh, India. Email:
   priyadev8090@gmail.com
- 8 2) Mohammad Ekhlak, PhD Scholar, Center for Advanced Research on Platelet
  9 Signaling and Thrombosis Biology, Department of Biochemistry, Institute of Medical
  10 Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India. Email:
  11 mohammadekhlakh02@gmail.com
- Ashish Yadav, Assistant Professor, Department of Biostatistics, Institute of Medical
   Sciences, Banaras Hindu University; Varanasi-221005, Uttar Pradesh, India. Email:
   ashstatbhu@gmail.com
- Debabrata Dash. M.D., D. Sc., Professor, Center for Advanced Research on Platelet
   Signaling and Thrombosis Biology, Department of Biochemistry, Institute of Medical
   Sciences, Banaras Hindu University; Varanasi-221005, Uttar Pradesh, India. Email:
   ddash.biochem@gmail.com
- S) Abhishek Pathak, M.D., D.M., Associate Professor, Department of Neurology,
   Institute of Medical Sciences, Banaras Hindu University, Varanasi-221005, Uttar
   Pradesh, India. Email: <u>abhishekpathakaiims@gmail.com</u>
- 22
- 23 **Disclaimer:** Priya Dev and Mohammad Ekhlak will be sharing 1<sup>st</sup> authorship.

# 24 Corresponding Author:

- 25 Dr. Abhishek Pathak, M.D., D.M.,
- 26 Associate Professor, Department of Neurology,
- 27 Institute of Medical Science, Banaras Hindu University,
- 28 Varanasi-221005, UP [INDIA]
- 29 Email:<u>abhishekpathakaiims@gmail.com</u>
- **30 Phone no.** +91 8948512666
- 31 Word count: Abstract: 176, Main text: 2846
- 32 **Tables: 3, Figure: 2**
- 33 Supplementary Tables:2
- 34 Supplementary Figure:2

#### 36 Abstract:

Background: Platelet-monocyte (PMA) and platelet-neutrophil aggregations (PNA) are
critical in causing acute inflammatory reactions favoring vascular dysfunction. However, the
precise pathophysiological link between Platelet-leukocyte aggregates and Vascular
Dementia (VaD) remains undetermined. Our study aimed to investigate whether platelet
hyperresponsiveness is independently associated with a predictor of VaD.

- 42 Methods: Platelet from 19 VaD patients and 18 age-matched healthy controls were subjected
- 43 to different investigations.

# 44 **Result:** PMA, PNA, P-selectin externalization, and intracellular free $Ca^{+2}$ ( $[Ca^{+2}_{i}]$ ) flux were

45 evaluated either in whole blood or in platelet-rich plasma. The result revealed that PMA,

46 PNA, P-selectin, and  $[Ca^{+2}]_i$  were found to be significantly outnumbered in the VaD group

47 (4.1, 2.8, 2.7, and 2.5 times higher) compared to the control group with p-value <0.001,

48 <0.001, <0.001, and 0.001 at 95% CI = 31.164 to 54.855, 8.653 to 22.793, 35.064 to 94.369

49 and 8747.015 to 28829.618 respectively.

50 Conclusion: Patients with Vascular Dementia have increased platelet leucocyte interaction,

and PMA has the most significant prediction of vascular dementia than in subjects of healthy

52 control. Thus, platelets in VaD patients switch to a 'hyperactive' phenotype.

53 Keywords: Platelet-monocyte aggregations, Platelet-neutrophil aggregations, P-selectin,

- 54 Vascular dementia, Platelet hyper-responsiveness
- 55
- 56
- 57
- 58

## 59 **INTRODUCTION:**

60 Vascular dementia (VaD) is a type of dementia marked by significant cognitive impairment 61 caused by an ischemic or haemorrhagic stroke or hypoperfusion of brain areas involved in 62 memory, cognition, and behaviour. The following lesions are the most common causes of 63 vascular dementia: ischemic lesions affecting large or small vessels (such as single strategic 64 strokes, multi-infarct dementia, small-vessel disease, lacunas, and venous occlusions); or 65 hypoperfusion lesions (including global or selective ischemia, border-zone infarcts, and 66 partial white matter ischemia).[1] VaD is the second most prevalent subtype of dementia after 67 Alzheimer's disease (AD), contributing to around 15% to 20% of dementia cases in North America and Europe, with slightly higher estimates of over 30% in Asia and developing 68 69 nations.[2-4] The overall risk of dementia following stroke varies greatly, ranging from 7% in 70 population-based studies of first-ever stroke in previously non-demented people to over 40% 71 in hospital-based studies of recurrent stroke with pre-stroke dementia.[5]

72 Stroke is still a well-known cause of dementia, increasing the risk by nearly two-fold.[6,7] 73 Stroke features, particularly severity and location, contribute to a significant portion of the 74 variability in dementia risk following a stroke.[8-11] Depending on education and premorbid cognitive performance, pre-existing medial temporal lobe atrophy, family history of 75 76 dementia, and comorbidities, patients may resist mental deterioration even after severe strokes.[5,8] Although dementia following a stroke is highest in the subacute period, it 77 78 continues for several years afterward, implying either a role for cognitive reserve or standard 79 etiological variables, such as cerebral small vessel disease. As previously stated, a closer 80 examination of the brain in old age frequently reveals a variety of pathologies, ranging from vascular pathologies such as macroscopic infarcts, microbleeds, micro infarcts, and amyloid 81 82 angiopathy to parenchymal amyloid and tau deposits, TDP (TAR DNA-binding protein)-43, 83 hippocampal sclerosis, and - synucleinopathies.[12-14] With a typical age of onset of

dementia in the community of over 80 years, nearly every patient coming to a nonspecialized memory clinic is likely to have a multifactorial aetiology of cognitive loss.[15]

86

87 Progressive VaD often culminates in acute thrombotic events. Crosstalk between platelets 88 and leukocytes influences primary and acute inflammatory reactions, favouring secondary 89 thrombosis at embolization locations. Leukocytes influence the inflammatory response as 90 well as vascular dysfunction. Platelet-leukocyte interaction contributes to the various phases 91 of ischemic stroke. Increased circulating levels of platelet neutrophil aggregates (PNAs) and 92 platelet monocyte aggregates (PMAs) are linked to direct cellular contacts between platelets 93 and innate leukocytes during the acute phase of stroke.[16] PNAs rise in the first three days 94 following an ischemic event, while PMAs are mostly observable on day two.[17] 95 Interestingly, platelet sequestration requires neutrophil adherence, suggesting that platelet 96 dysfunction is not the primary cause of post-ischemic vascular dysfunction.[18] The 97 interaction between platelets and leukocytes is thought to promote inflammatory processes 98 and tissue damage by increasing leukocyte activation and recruitment.[19] Platelet-leukocyte 99 interactions are mediated by P-selectin (CD62P) and CD40L-CD40, which are elevated in 100 platelets of patients with acute stroke or transient ischemic attack; [20] enhance brain damage 101 by facilitating leukocyte activation recruitment, increasing BBB permeability, and increasing 102 the infarct volume.[18,21]

103 The precise pathophysiological link between Platelet-leukocyte aggregates and VaD yet 104 remains undetermined. Although platelet-leukocyte interactions have been studied in ADs 105 patients, the study in VaD will help us in differential diagnosis with a more precise subtype 106 diagnosis beyond a coarse clinical cognitive phenotype. This study aims to study the 107 association of PMA, PNA, P-selectin, and calcium levels as a part of platelet function in 108 vascular dementia patients compared to healthy control. This study will guide us towards a

109 better approach in treatment decisions depending upon pathways implicated in VaD patients,

110 notably those of vascular origin. So, we aim to study the crosstalk between platelet and

111 leukocytes in VaD patients.

#### 112 **METHODOLOGY:**

#### **113 Patient selection**

Vascular dementia was diagnosed based on the National Institute of Neurological Disorders and Stroke-Association Internationale pour la recherche et l'Enseignement en Neurosciences (NINDS AIREN) Criteria; Cognitive functions were assessed by MMSE, and a complex cognitive function was evaluated. All consecutive patients with vascular dementia who were admitted or visited the outpatient department were enrolled in the study. General inclusion/exclusion criteria were as follows:

#### 120 Inclusion criteria

121 (1) Control subjects: these individuals were fully independent in the activities of daily living 122 (ADL), and instrumental activities of daily living (IADLs); (2) Probable VaD: meet the 123 National Institute of Neurological Disorders and Stroke- Association Internationale pour la 124 Recherche et l'Enseignement en Neurosciences (NINDS AIREN) Criteria; (Diagnosis of type 125 2 diabetes (DM) was based on American Diabetes Association criteria such as fasting plasma 126 glucose of 7.0mmol/L, current treatment with a hypoglycaemic agent, casual glucose of 127 11.1mmol/L. For the controls or the patients with impaired fasting glucose DM was 128 diagnosed if a 2-hour post-glucose level after an approx. 75-g oral glucose tolerance test 129 11.1mmol/L. Hypertension was diagnosed if systolic blood pressure >140mmHg and 130 Diastolic pressure >90mmHg, or as antihypertensive treatment. Two readings were taken 131 with a 5-minute interval between measurements. The mean of the two readings was recorded. 132 CAD (coronary athero- sclerotic heart disease) was defined as the occurrence of a non-fatal

myocardial infarction, percutaneous coronary angioplasty, or other forms of acute or chronicischemic heart disease.

The diagnostic evaluation included: Non-Contrast Computed Tomography (NCCT) or Brain Magnetic resonance imaging (MRI), hemogram, biochemical tests, electrocardiogram, transoesophageal echocardiography, vascular imaging (intra- and extra-cranial vessels), assessment of prothrombic state. The patient also underwent 24 h Holter monitoring to rule out any atrial fibrillation.

#### 140 Exclusion criteria

Exclusion criteria for this study included other psychiatric diseases, chronic alcoholism, tumour, infection, haematological disorders, atrial fibrillation, chronic liver and kidney diseases, abnormal vitamin B12 or thyroid function tests, depression (as indicated by a score of 410 on the Geriatric Depression Scale), Parkinson's disease, therapeutic use of anticoagulant for various medical conditions and dementia treatment.

146

#### 147 Sample preparation

148 Blood from patients diagnosed with VaD (n=19) was collected within seven days of VaD 149 onset from the forearm venepuncture with minimal stasis to avoid platelet stimulation. 150 Sample from age-matched healthy control (n=18) with no history of a relevant disease or 151 medication within a year was collected after obtaining written informed consent, strictly as 152 per recommendations and approved by the Institutional Ethical Committee of the Institute of 153 Medical Sciences, Banaras Hindu University. The study methodologies conformed to the 154 standards set by the Declaration of Helsinki. Blood was processed within 20 min of 155 collection. Whole blood was employed for the platelet-leucocyte interaction experiment.

Blood was centrifuged at  $100 \times g$  for 20 min at room temperature to obtain platelet-rich plasma (PRP), used for P-selectin externalization and intracellular calcium measurement studies.[22]

#### 159 Platelet monocyte and neutrophil aggregation

160 Fresh human blood (20 µl) was added to a cocktail containing 10 µl each from APC-161 anti-CD41a (platelet-specific) (Hu CD41a APC HIP8; Cat no.: 559777) and FITC-anti-CD14 162 (leukocyte-specific) antibodies (Hu CD14 FITC M5E2; Cat no.:555397) and mixed gently. 163 RBCs were lysed with 800 µl FACS lysis solution (1X, BD Biosciences) (BD FACS Lysing 164 Solution 10X 100ML IVD; Cat no.: 349202) for 10 min at RT. Leucocyte-platelet interaction 165 was analysed on a flow cytometer (FACS Calibur, BD Biosciences) within 30 min. Side 166 scatter voltage was set at 350 with a threshold of 52 V, and amorphous gates were drawn to 167 encompass neutrophils and monocytes separate from noise. A dot plot of side scatters (SSC) 168 versus log FITC-CD14 fluorescence was created in the CellQuest Pro software. Amorphous 169 gates were drawn for monocyte (high fluorescence and low SSC) and neutrophil (low 170 fluorescence and high SSC) populations. All fluorescence data were collected using 4-171 quadrant logarithmic amplification for 1000 events in either neutrophil or monocyte gate 172 from each sample and analysed using CellQuest Pro Software.

173

#### **174** Secretion from platelet α-granules

175 Secretion from platelet  $\alpha$ -granules in response to a stimulus was quantified by surface 176 expression of P-selectin (CD62P). Briefly, 50 µl PRP were taken, and cells were stained with 177 FITC-labelled anti-CD62P antibody (Hu/NHP CD62P PE AC1.2; Cat no.: 550561) (5 % v/v) 178 for 30 min at room temperature in the dark. Samples were suspended in sheath fluid and

179	subjected to flow cytometry. The acquisition was performed on a constant number	of
180	particles (10,000 events), and the results were expressed as the mean of positive platelets.	

181

182

# 183 Measurement of intracellular free calcium $([Ca^{+2}]_i)$

184 PRP (5 µl) was diluted in 495 µl buffer B (20 mM HEPES, 138 mM NaCl, 2.9 mM 185 KCl, 1 mM MgCl<sub>2</sub>, 0.36 mM NaH<sub>2</sub>PO<sub>4</sub>, supplemented with 5 mM glucose, pH 7.4). Fluo-186 4/AM was added to each tube and was incubated for 30 min at room temperature. After 187 appropriate gating of platelets using a flow cytometer (Becton Dickinson, model Accuri C6), 188 events were analysed in the FL1 channel within the time-lapse of 1.5–4.0 min (in the upper 189 right quadrant) following the addition of reagents. Baseline calcium levels were recorded for 190 60 s, followed by the addition of 1 mM CaCO<sub>3</sub> and five  $\mu$ M TRAP using gel-loading pipette 191 tips as described by Mallick et al., 2015.[23]

192

## 193 Flow cytometry acquisition and interpretation of data

194 Flow cytometry was performed using a FACS Calibur instrument with CELLQuest software 195 (Becton Dickinson Immunocytometry Systems). Forward and side scatter measurements were 196 made with gain settings in linear mode to analyse platelet-monocyte or platelet-neutrophil 197 interactions. The monocyte and the neutrophil populations were thus easily distinguished 198 (Figure 1A, 1B). A minimum of 2000 monocytes and 5000 neutrophils were acquired for 199 each determination. A three-color analysis was used for the simultaneous detection of 200 platelet-leukocyte aggregates and platelet-leukocyte activation. Monocytes and neutrophils 201 were further gated into a CD41a-positive platelet-bound population, gate two, and a CD41a-202 negative platelet-free population, gate three (FL1 versus FL4, Figure 1A, 1B). Unbound

203	platelets were measured with forwarding and side scatter signals in logarithmic mode. Ten
204	thousand events were acquired with a live gate on FSC versus SSC. Results were compared
205	to antibody-matched controls and expressed as positive percentage cells or mean fluorescence
206	intensity (MFI) after subtracting the control antibodies.

207

#### 208 **Ethical Statement:**

The Institutional ethical committee of the Institute of Medical Sciences, Banaras Hindu University, UP, India, received approval for a study protocol. All participants, before enrolment, read the study protocol and signed informed consent to have been included in the study. The study was conducted by the Declaration of Institutional ethics committee.

213

## 214 Statistical Evaluation:

The statistical analysis was performed with the SPSS v16. The obtained data were expressed as mean and standard deviation. The student's t-test was performed to determine statistical significance. The level of p < 0.05 was considered the threshold for statistical significance. ROC curve was drawn in a post hoc analysis to determine the cut-off value of the plateletleukocyte experiment variables for the diseased and control group. Further, principal component analysis (PCA) to select the explanatory variable for the logistic regression model.

222

#### 223 **Results:**

The study involved 19 VaD patients (with a mean age of  $63.63\pm12.35$  years) and 18 age and gender-matched healthy control subjects (with a mean age of  $60.22\pm14.17$  years). Their demographic data is represented in table 1.

Out of 19 VaD patients, 79% were male; all had a history of ischemic stroke; 17 patients had partial anterior circulation infarct (PACI) and two patients had Lacunar infarct (LACI); 10 patients were Small vessel disease (SVD), seven were cardioembolic, and 2 were cryptogenic stroke in origin in TOAST classification; 52.6% had a history of hypertension, and 26.3% patients had periventricular white matter (PWM) changes with Fazekas grade 3. (Table 1)

232

233 An independent sample t-test was used to analyse the PMA, PNA, P-selectin, and  $[Ca^{+2}]_i$ 

level between VaD patients and control subjects. The result revealed that PMA (fig 1A), PNA

(fig 1B), P-selectin (fig 2A), and  $[Ca^{+2}]_i$  (fig 2B) were found to be significantly higher in the

VaD group (4.1, 2.8, 2.7, and 2.5 times higher) compared to the control group with p-value

237 <0.001, <0.001, <0.001, and 0.001 at 95% CI = 31.164 to 54.855, 8.653 to 22.793, 35.064 to

238 94.369 and 8747.015 to 28829.618 respectively. (Table 1) (Fig 1 and 2)

239

The post hoc analysis was used to draw a ROC curve to determine the cut-off value for PMA (with the area under the ROC curve (AUC)= 0.988), PNA (AUC=0.944), p-selectin (AUC=0.819) and  $[Ca^{+2}]_i$  (AUC=0.871) variables for discrimination VaD from the control group. Thus, the cut-off value was determined as 22.35% (sensitivity=94.7% and specificity=100%), 17.00% (sensitivity=78.9% and specificity=100%), 61.37 MFI (sensitivity=78.9% and specificity=78%), and 18778.5 MFI (sensitivity=78.9% and specificity=78%) for PMA, PNA, P-selectin and  $[Ca^{+2}]_i$  variables respectively. (Table 2)

247

The predictor variables PMA, PNA, P-selectin, and  $[Ca^{+2}]_i$  were highly correlated the value of the Pearson correlation coefficient lies in the range from 0.65 to 0.84. The problem of collinearity was addressed using a multivariate approach called principal component analysis (PCA). PCA results suggest that the first component, i.e., PMA had the highest eigenvalues

and then is PNA's value. But in supplementary table 1, we can observe that in the control group there is a significant (P=0.0014) association (r=0.69) between PMA and PNA, and rest of the covariates are not correlated. One can observe a circular representation of a scatter plot from Supplementary Figure 1 representing a week correlation. Similarly, we can observe that in the diseased group, except for P-selectin and PNA rest, all the covariates are significantly associated with each other (Supplementary Table 2). The exact inference can be observed in Supplementary Figure 2, where a positive linear trend is observed between the covariates.

Thus, finally, a logistic regression model with the group as outcome variables (PNA, Pselectin, and  $[Ca^{+2}]_i$ ), as an explanatory variable was developed however, the models suggest that out of them, only PNA as an explanatory variable was statistically significant. (Table 3) Table 3 shows that PNA is a significant predictor variable in explaining VaD disease and alone can explain 38% of the variation.

264

#### 265 **Discussion:**

Our result shows that all the platelet functions, namely, PMA, PNA, p-selectin, and  $[Ca^{+2}]$  I, 266 267 are significantly increased in VaD compared to control. The post- hoc analysis concluded that 268 PMA had the eigenvalue in Vascular Dementia compared to the control. This is the first study 269 with the above-mentioned parameters looking into the platelet activity in Vascular dementia 270 vis-a-vis age and sex-matched control patients. The increased platelet activity has been 271 implicated in the development of Alzheimer's Disease but their role in the development of 272 Vascular Dementia has not been studied adequately. Vascular Dementia has been implicated 273 to have an underlying inflammatory cascade. The role of platelets during the inflammatory 274 state interacts with leucocytes via various soluble mediators and direct cell-based 275 interactions. Platelet has the highest affinity for macrophages and monocytes, followed by 276 neutrophils. Cell-based interaction includes activation of CXCL4, which prevents monocyte

277 apoptosis and, along with other cell-based receptors, namely CD40L and CD62P, promotes 278 the production of cytokines and ROS. Increased platelet activity has a significant contribution 279 to the development of vascular dementia. In a similar study done by Konstantinos Stellos et 280 al. on 37 patients found that higher platelet activity was seen in patients with Vascular 281 cognitive impairment similar to our study. Leucoariosis has independently been associated 282 with the development of Vascular Cognitive impairment. Fujita et al. studied the platelet 283 hyperaggregability in the development of leukoaraiosis in 73 patients and they concluded that 284 patients with leukoaraiosis had significantly higher platelet hyperaggregability than patients 285 without leukoaraiosis. In a similar study done by Nagamo Kuriyama et al., in 143 subjects 286 with deep white matter lesions(DWML) with cognitive decline, found significant increases in 287 hypertension and CD62P levels with increasing DWML grade. This study also observed a 288 significant negative correlation between CD62P levels and MMSE scores. Our study did not 289 directly look into DWML but our patient group also had patients with DWML and vascular 290 cognitive impairment.

The increased platelet activity contributes to cognitive impairment through several mechanisms. Firstly, platelet-bound GPIIb-IIIa and P-selectin interaction lead to increased adhesion, rolling, recruitment, and diapedesis of platelets on endothelial cells, ultimately leading to vascular and perivascular inflammation leading to dementia progression. Secondly, it also leads to progressive carotid atherosclerosis, an independent risk factor for vascular dementia independently, via various secondary mechanisms, including vasoconstriction and hypoxia.

Our study had a few advantages; first, this was one of the first studies to look into the platelet leucocyte interaction in patients with Vascular dementia. Secondly, the assessor of platelet leucocytes was blinded to the samples of Vascular dementia and healthy control. Thirdly the

patient was purely of Vascular dementia, and none of the patients with mixed dementia wereincluded.

303 Our present study had a few major limitations. Firstly, the sample size of the patients was 304 very small. Secondly, the other types of dementia could also have been chosen as a control, 305 namely FTD, AD, and DLBD. Thirdly whether increased platelet interaction is the cause or 306 the effect cannot be proven by the present study. To prove its causality, a prospective study 307 with intermittent platelet activity with a larger population of patients with vascular risk 308 factors developing into Vascular dementia should be studied. 309 However, this study indicates that drugs that would inhibit platelet leucocyte interaction may 310 have the potential for therapeutic importance in patients with vascular dementia. 311 312 Conclusion: Patients with Vascular Dementia have increased platelet leucocyte interaction, 313 and PMA has the most significant prediction of vascular dementia than in subjects of healthy 314 control. Inhibiting this platelet leucocyte interaction may have a therapeutic advantage. 315 However, larger prospective studies with a larger population of vascular dementia are 316 required to prove the present hypothesis.

317

#### 318 Acknowledgements

319 I would like to thank BHU and Sir Sunder Lal Hospital for their infrastructural support.

320 Sources of Funding:

This research was supported by Institution of Eminence (IOE) grant BHU (grant number
42872) received by A. Pathak.

323 Conflict-of-interest disclosure: The Author(s) declare(s) that there is no conflict of interest

## 324 Statement of Ethics:

- 325 -Study approval statement: This study protocol was reviewed and approved by Institutional
- 326 Ethics Committee, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India,
- and Reference number [Dean/2020/EC/2155]
- 328 -Consent to participate statement: WRITTEN informed consent was obtained from
- 329 participants or legal guardian to participate in the study.
- **Funding sources:** This research was supported by IOE (Institution of Eminence) Banaras
- Hindu University. IOE Grant number: 42872.
- 332 Data Availability Statement: All data generated or analysed during this study are included
- in this article and its supplementary material file.
- 334 Authors agreement: All authors have viewed and agreed to the submission
- 335 **Consent for publication:** Not applicable
- 336 **Consent for publication:** Not applicable
- **Author Contributions:** PD: Experiments, paper writing and editing; ME: experiments; AY:

338 Statistical analysis; DD: provided instruments facility for Experiments; AP:

339 conceptualization, paper editing, writing

## 341 **References:**

342	1.	Gustavo C. Román, in Neurology and Clinical Neuroscience, 2007
343	2.	Jhoo J H, Kim KW, Huh Y, Lee S B, Park J H, Lee J J and others (2008).
344		Prevalence of dementia and its subtypes in an elderly urban korean population:
345		results from the Korean Longitudinal Study on Health And Aging (KLoSHA).
346		Dementia and geriatric cognitive disorders, 26(3), 270–276.
347		https://doi.org/10.1159/000160960
348	3.	Chan K Y, Wang W, Wu J J, Liu L, Theodoratou E, Car J, and others (2013).
349		Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-
350		2010: a systematic review and analysis. Lancet (London, England), 381(9882),
351		2016-2023. https://doi.org/10.1016/S0140-6736(13)60221-4
352	4.	Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K and others
353		(2008). Alzheimer's disease and vascular dementia in developing countries:
354		prevalence, management, and risk factors. The Lancet. Neurology, 7(9), 812-826.
355		https://doi.org/10.1016/S1474-4422(08)70169-8
356	5.	Pendlebury ST and Rothwell PM (2009). Prevalence, incidence, and factors
357		associated with pre-stroke and post-stroke dementia: a systematic review and meta-
358		analysis. The Lancet. Neurology, 8(11), 1006–1018. https://doi.org/10.1016/S1474-
359		<u>4422(09)70236-4</u>
360	6.	Wolters FJ and Ikram MA (2018). Epidemiology of Dementia: The Burden on
361		Society, the Challenges for Research. Methods in molecular biology (Clifton, N.J.),
362		1750, 3–14. https://doi.org/10.1007/978-1-4939-7704-8_1
363	7.	Kuźma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ (2018).
364		Stroke and dementia risk: A systematic review and meta-analysis. Alzheimer's &

365		dementia : the journal of the Alzheimer's Association, 14(11), 1416–1426.
366		https://doi.org/10.1016/j.jalz.2018.06.3061
367	8.	Pendlebury ST, Rothwell PM, Oxford Vascular Study (2019). Incidence and
368		prevalence of dementia associated with transient ischaemic attack and stroke:
369		analysis of the population-based Oxford Vascular Study. The Lancet. Neurology,
370		18(3), 248–258. https://doi.org/10.1016/S1474-4422(18)30442-3
371	9.	Munsch F, Sagnier S, Asselineau J, Bigourdan A, Guttmann CR, Debruxelles S,
372		(2016). Stroke Location Is an Independent Predictor of Cognitive Outcome. Stroke,
373		47(1), 66–73. https://doi.org/10.1161/STROKEAHA.115.011242
374	10.	Tatemichi TK, Desmond DW, Prohovnik I, Cross DT, Gropen T I, Mohr J P
375		(1992). Confusion and memory loss from capsular genu infarction: a
376		thalamocortical disconnection syndrome?. Neurology, 42(10), 1966–1979.
377		https://doi.org/10.1212/wnl.42.10.1966
378	11.	Mok VC, Lam B Y, Wong A, Ko H, Markus HS, Wong LK (2017). Early-onset and
379		delayed-onset poststroke dementia - revisiting the mechanisms. Nature reviews.
380		Neurology, 13(3), 148–159. https://doi.org/10.1038/nrneurol.2017.16
381	12.	Portegies ML, Wolters FJ, Hofman A, Ikram MK, Koudstaal PJ, Ikram MA (2016).
382		Prestroke Vascular Pathology and the Risk of Recurrent Stroke and Poststroke
383		Dementia. Stroke, 47(8), 2119–2122.
384		https://doi.org/10.1161/STROKEAHA.116.014094
385	13.	Boyle P A, Yu L, Wilson RS, Leurgans SE, Schneider J A, Bennett DA (2018).
386		Person-specific contribution of neuropathologies to cognitive loss in old age.
387		Annals of neurology, 83(1), 74-83. https://doi.org/10.1002/ana.25123
388	14.	Stephan BC, Matthews FE, Ma B, Muniz G, Hunter S, Davis D and others (2012).
389		Alzheimer and vascular neuropathological changes associated with different

390	cognitive States in a non-demented sample. Journal of Alzheimer's disease : JAD,
391	29(2), 309–318. https://doi.org/10.3233/JAD-2011-110518
392	15. Wolters FJ, van der Lee SJ, Koudstaal PJ, van Duijn CM, Hofman A, Ikram MK,
393	and others (2017). Parental family history of dementia in relation to subclinical
394	brain disease and dementia risk. Neurology, 88(17), 1642-1649.
395	https://doi.org/10.1212/WNL.000000000003871
396	16. Ishikawa T, Shimizu M, Kohara S, Takizawa S, Kitagawa Y, Takagi, S. (2012).
397	Appearance of WBC-platelet complex in acute ischemic stroke, predominantly in
398	atherothrombotic infarction. Journal of atherosclerosis and thrombosis, 19(5), 494-
399	501. <u>https://doi.org/10.5551/jat.10637</u>
400	17. Marquardt L, Anders C, Buggle F, Palm F, Hellstern P, Grau AJ (2009). Leukocyte-
401	platelet aggregates in acute and subacute ischemic stroke. Cerebrovascular diseases
402	(Basel, Switzerland), 28(3), 276–282. https://doi.org/10.1159/000228710
403	18. Ishikawa M, Cooper D, Arumugam TV, Zhang J H, Nanda A, Granger DN (2004).
404	Platelet-leukocyte-endothelial cell interactions after middle cerebral artery
405	occlusion and reperfusion. Journal of cerebral blood flow and metabolism: official
406	journal of the International Society of Cerebral Blood Flow and Metabolism, 24(8),
407	907-915. https://doi.org/10.1097/01.WCB.0000132690.96836.7F
408	19. Htun P, Fateh-Moghadam S, Tomandl B, Handschu R, Klinger K, Stellos K,
409	Garlichs C, and others (2006). Course of platelet activation and platelet-leukocyte
410	interaction in cerebrovascular ischemia. Stroke, 37(9), 2283–2287.
411	https://doi.org/10.1161/01.STR.0000236638.75591.61
412	20. Lukasik M, Dworacki G, Michalak S, Kufel-Grabowska J, Watala C, Kozubski W
413	(2012). Chronic hyper-reactivity of platelets resulting in enhanced monocyte

- 414 recruitment in patients after ischaemic stroke. *Platelets*, 23(2), 132–142.
- 415 https://doi.org/10.3109/09537104.2011.597528
- 416 21. Ishikawa M, Vowinkel T, Stokes KY, Arumugam TV, Yilmaz G, Nanda A and
  417 others (2005). CD40/CD40 ligand signaling in mouse cerebral microvasculature
  418 after focal ischemia/reperfusion. *Circulation*, *111*(13), 1690–1696.

419 <u>https://doi.org/10.1161/01.CIR.0000160349.42665.0C</u>

- 420 22. Wiśniewski A, Filipska, K. (2020). The Phenomenon of Clopidogrel High On421 Treatment Platelet Reactivity in Ischemic Stroke Subjects: A Comprehensive
  422 Review. *International journal of molecular sciences*, 21(17), 6408.
  423 <u>https://doi.org/10.3390/ijms21176408</u>
- 424 23. Mallick RL, Kumari S, Singh N, Sonkar VK, Dash D (2015). Prion protein
  425 fragment (106-126) induces prothrombotic state by raising platelet intracellular
  426 calcium and microparticle release. *Cell calcium*, 57(4), 300–311.
- 427 <u>https://doi.org/10.1016/j.ceca.2015.02.002</u>

## 429

# Tables

# 430 Table 1: Baseline demographic and clinical data of VaD patients and Control

Sl.	Variables	VaD (N=19)	Control (N=18) (Mean+SD)	P-Value	95% CI	
110.			(Weall_SD)			I
1		(2.(2.12.25	(0.00.14.17	0.4400	Lower	Upper
1	Age (mean $\pm$ SD)	63.63±12.35	60.22 14.17	0.4400	-5.447	12.266
2	NIHSS	16.42±5.83				
3	GCS (Out of 15)	12±2.91				
4	PMA (%)	57.5	14.1	0.0000	31.164	54.855
5	PNA (%)	24.5	8.8	0.0001	8.653	22.793
б	P-sel (MFI)	103.140± 54.971	38.423±29.334	0.0001	35.064	94.369
7	Ca <sup>++</sup>	30948.595± 20014.593	12160.278±436.038	0.0006	8747.015	28829.618
8	Male (%)	15(78.9)	16(88.9)	0.412		
9	History of Stroke (%)	19(100)				
10	Location of the stroke (%	)				
	PACI	17(89.5)				
	LACI	2(10.52)				
11	TOAST classification (%)	)				
	SVD	10(52.6)				
	Cardioembolic	7(36.8)				
	Cryptogenic	2(10.5)				
12	History of comorbidities (	(%)		I.		
	HTN (Yes)	10(52.6)	0	0.000		
	DM(Yes)	2(10.5)	0	0.213		
	Dyslipidemia	1	0	0.324		
13	Fazekas (%)					
	0					
	1	5(26.3)				
	2	9(47.4)				
	3	5(26.3)				
14	Hemisphere (%)		1	1		1
	Right	2(10.6)				
L						1

	Left	3(15.8)					
	Bilateral	14(73.7)					
15	MRS (%)						
	3	2(10.5)					
	4	5(26.3)					
	5	11(57.9)					
	6	1(0.3)					
16	MRS Follow-up (%)						
	2	1(5.3)					
	3	4(21.1)					
	4	5(26.3)					
	5	3(15.8)					
	6	6(31.6)					

# **Table 2: Area under the curve (ROC table)**

Variables	Area	Standard- Error	P-Value	95% CI	
				UPPER	LOWER
PMA	0.988	0.013	0.000	0.962	1.015
PNA	0.944	0.034	0.000	0.878	1.011
P-Selectin	0.819	0.071	0.001	0.680	0.958
Ca <sup>++</sup>	0.817	0.061	0.000	0.752	0.990

# 435 Table 3: Factor correlation and Logistic Regression analysis

Variables	Factor correlation	Logistic Regression		
	Eigen's value	β-coefficient	95%	6 CI
			UPPER	LOWER
РМА	0.988			
PNA	0.944	0.3822	0.028	0.042
P-Selectin	0.819	-0.0022	0.913	-0.042
Ca <sup>++</sup>	0.817	0.0002	0.093	-0.000

# 438 Figure Legends

439	•	Figure 1: Detection of platelet-monocyte and platelet-neutrophil aggregates in
440		circulation: A and B, flow cytometric analysis of monocyte-platelet and neutrophil-
441		platelet aggregates, respectively, in whole blood stained with platelet-specific marker,
442		anti-CD41a-APC and neutrophil/monocyte-specific marker, anti-CD14-FITC.
443		Samples were obtained from control and different vascular dementia (VaD) groups as
444		indicated. Amorphous gates were drawn for monocyte (high fluorescence and low
445		SSC) and neutrophil (low fluorescence and high SSC) populations. Numbers in right
446		upper quadrant represent percent of aggregates. C and D, corresponding scatter plot
447		bar diagrams representing mean percent of PMA and PNA, respectively.

# Figure 1



Figure 2. Exposure of P-selectin on surface of unstimulated platelets and determination of platelet population with raised intracellular calcium:: A, flow cytometric analysis of binding of anti-P-selectin antibody to surface of unstimulated platelets from VaD group and control group as indicated (representing mean fluorescence intensity). B, flow cytometry of Fluo-4-labeled platelets representing cell population with high fluorescence intensity in control (n=18), and VaD (n=19) groups, respectively, (representing mean fluorescence intensity over 1.5 min of a population before TRAP addition). 







### • Supplementary Figure 1: Scattered plot showing correlation between predictor

## 469 variables in control group



470

- **Supplementary Figure 2:** Scattered plot showing predictor variable in diseased
- 472 group



# 474 Supplementary Tables

	PNA	PMA	P-selectin	$[Ca^{+2}]_{i}$
PNA	1.0000			
PMA	0.6936	1.0000		
(p-value)	(0.0014)			
P-selectin	0.0896	-0.0124	1.0000	
(p-value)	(0.7237)	(0.9610)		
$[Ca^{+2}]_i$	-0.0708	0.2172	0.1808	1.0000
(p-value)	(0.7802)	(0.3866)	(0.4727)	

# 475 Supplementary Table 1: Correlation between Predictors for Control group

476

## 477 Supplementary Table 2:-Correlation between Predictors for Case group

	PNA	PMA	P-selectin	$[Ca^{+2}]_i$
PNA	1.0000			
PMA	0.7447	1.0000		
(p-value)	(0.0003)			
P-selectin	0.2724	0.5214	1.0000	
(p-value)	(0.2592)	(0.0192)		
$[Ca^{+2}]_i$	0.5154	0.5689	0.6952	1.0000
(p-value)	(0.0239)	(0.0110)	(0.0010)	

478



